NASDAQ
8.84USD
+0.78 (+9.68%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
570.4M
P/E
—
EPS
—
Beta
1.74
52W range
6.06-14.51
Day range
8.45–9.65
Open
8.45
Prev close
8.06
Volume
1.9M
Avg volume
787.7K
Dividend
0.00
IPO
2018-09-27
https://www.zacks.com/stock/news/2967333/arvinas-inc-arvn-beats-q2-earnings-and-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|yseop_template_4-2967333 · 8/4/2026+0.80
https://www.marketbeat.com/instant-alerts/bilibili-q1-earnings-call-highlights-2026-05-19/ · 5/19/2026+0.70
https://www.zacks.com/stock/news/2874337/arvinas-inc-arvn-reports-q4-loss-misses-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2874337 · 2/24/2026-0.80
https://www.globenewswire.com/news-release/2025/11/03/3179086/0/en/Arvinas-to-Participate-in-Upcoming-Investor-Conferences.html · 11/3/2025+0.80
https://www.globenewswire.com/news-release/2025/10/05/3161349/0/en/Arvinas-Presents-Late-Breaking-Positive-Phase-1-Clinical-Data-for-ARV-102-a-PROTAC-LRRK2-Degrader-at-the-2025-International-Congress-of-Parkinson-s-Disease-and-Movement-Disorders.html · 10/5/2025+1.00
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
